Recent Treatment Advances in Inflammatory Bowel Disease: Greater Outcomes through Personalized Approaches

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2020 to March 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Celgene and Takeda Pharmaceuticals USA, Inc.

Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1.6 million people in the United States, with as many as 70,000 new cases diagnosed each year. This lifelong, systemic autoimmune illness often strikes patients at a young age and must be managed across a lifetime. Imaging plays a critical role in the initial diagnosis and ongoing evaluation of IBD patients. There is no cure for IBD, and the immediate treatment goal is to decrease inflammation in order to reduce and control symptoms. Long-term treatment goals include reaching clinical remission and maintenance through mucosal healing, preventing further complications, and ultimately improving patient quality of life. Several treatment options are available and emerging therapies are currently being developed. Aminosalicylates are the mainstay of first line therapy in treating IBD and are useful for healing flares and maintaining remission. Antibiotics are available to treat bacterial infections, corticosteroids are rapid-acting anti-inflammatory agents that are indicated for acute flares of disease, and immunomodulators have a slower onset of action and work to reduce patients’ overactive immune system. The most recent advances in IBD therapy include biologics, which are proteins that stop certain molecules in the body from causing inflammation in the GI tract. These are usually prescribed to patients living with moderate to severe cases of IBD who haven’t responded to other types of treatment. Advances in these treatments and the presence of biologic therapies are changing goals and expectations of IBD management while providing patients a better chance of achieving remission and improving quality of life.

Upon completion of this activity, participants will be able to:

  • Evaluate the current and novel treatment options based on their clinical safety, efficacy and patient-specific characteristics

  • Discuss recommended guidelines and the impact early diagnosis can have on effective IBD management

  • Identify patients with IBD who are at risk of the overreliance of corticosteroids and may benefit from biologic therapies

  • Explore strategies for patients who would benefit from emerging non-biologic agents
    Evaluate the different challenges associated with IBD, including adherence, comorbidities, and steroid resistance

  • Assess personalized treatment strategies for patients with complex IBD

Faculty: Joseph Feuerstein, MD
Associate Clinical Chief, Gastroenterology
Center For Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Assistant Professor of Medicine
Harvard Medical School


Dr. Feuerstein has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Celgene and Takeda Pharmaceuticals USA, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue